Abeona’s ZEVASKYN Launch is Moving from Approval to Execution

For Abeona Therapeutics (NASDAQ: ABEO), the ZEVASKYN story is shifting from regulatory achievement to something more measurable: how many patients can make it through treatment, and how reliably those treatments turn into revenue.

The second quarter offered early evidence of progress.

Abeona treated five patients with ZEVASKYN during the quarter, up from three in the first quarter, and another three had been treated in the third quarter through August 13. Twelve patients have now received the treatment since launch. Net ZEVASKYN revenue rose 31% sequentially to $11.4 million.

For a rare-disease launch measured in individual patients rather than thousands of prescriptions, those numbers matter quickly.

Seven Centers, Twelve Patients

ZEVASKYN is the first and only autologous cell-based gene therapy approved to treat wounds in adults and children with recessive dystrophic epidermolysis bullosa, or RDEB. Getting it to patients is considerably more complicated than filling a prescription. Patients must move through a qualified treatment center, insurance and access requirements, biopsy collection, manufacturing and ultimately treatment.

That makes the treatment-center network an important part of the commercial story. Seven QTCs are now active nationwide. NewYork-Presbyterian/Columbia and Children’s Hospital of Philadelphia joined during the second quarter, while Cincinnati Children’s, one of the country’s largest epidermolysis bullosa treatment centers, was activated in Q3.

More important, centers are beginning to move beyond activation. CHOP and the University of Texas Medical Branch have started collecting patient biopsies, and CHOP has already treated its first patient.

Abeona previously said more than 100 potential patients had been identified through treatment centers and community physicians. That isn’t a 100-patient backlog, but it does suggest the issue may increasingly become how efficiently Abeona can move patients through the system.

Four Treatments, $11.4 Million

Abeona generated $11.4 million in Q2 ZEVASKYN revenue despite recognizing revenue from only four of the five patients treated during the quarter.

H.C. Wainwright estimates that Abeona could reach cash-flow breakeven at roughly 35 to 40 treatments annually, corresponding to more than $100 million in revenue. Its current estimates call for $50.2 million in 2026 revenue and $95 million in 2027.

That puts the commercial question into fairly simple terms. Abeona doesn’t need hundreds of treatments each quarter for the financial profile to change materially. It needs to demonstrate that a growing network of treatment centers can produce a consistent flow of successful treatments.

The Manufacturing Variable

Two of the 12 patients treated since launch have not resulted in recognized revenue because of manufacturing yield or lot-release specification issues. In Q2, one batch produced fewer than the threshold number of sheets required for revenue recognition.

At this stage of the launch, two cases aren’t enough to establish a pattern. But they are enough to make manufacturing consistency a metric worth watching.

For an autologous cell-based gene therapy, adding patients to the funnel only solves half the problem. Abeona also has to consistently turn patient biopsies into releasable commercial product.

There is room for the economics to improve with scale. Q2 gross margin was approximately 63%, while management has indicated margins could eventually reach roughly 85% to 90% at full facility utilization.

NTAP Starts October 1

Beginning October 1, ZEVASKYN will receive New Technology Add-On Payment status from CMS, allowing eligible hospitals to receive supplemental reimbursement above the standard inpatient payment when treating Medicare beneficiaries.

Medicare represents only about 10% of the RDEB population, so NTAP alone isn’t likely to transform demand. But it removes another potential point of friction for hospitals as Abeona tries to broaden adoption.

The company also ended June with $146.8 million in cash, cash equivalents and short-term investments. H.C. Wainwright believes that is sufficient to fund operations through potential cash-flow breakeven and continues to rate ABEO a Buy with a $20 price target. The stock closed August 21 at $6.09.

The Launch Is Becoming Measurable

ZEVASKYN is still early in its commercial life, which makes extrapolating from a dozen treatments risky. But the metrics investors need to watch are becoming clearer.

The number of treatment centers is growing. More centers are moving patients into biopsy and treatment. Treatment cadence increased from three patients in Q1 to five in Q2, with another three already completed early in Q3. Revenue is following.

Now Abeona has to show that those pieces can work together consistently. The next phase of the ZEVASKYN launch may come down to three numbers: patients treated, treatments successfully converted into revenue, and the time it takes to move patients through the expanding QTC network.

If those numbers continue moving in the right direction, Abeona’s commercial story could begin looking very different from the development-stage biotech investors knew before ZEVASKYN’s launch.